Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of NVP-1805 vs Coadministration of NVP-1805-R1 and NVP-1805-R2
NCT05354713Phase 1Completed
- Sponsor
- NVP Healthcare Co., Ltd.
- Start
- Nov 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NVP-1805 in hypertension (HTN) and dyslipidemia (2 arms), sponsored by NVP Healthcare Co., Ltd. Primary endpoints: NVP-1805's Pharmacokinetics of plasma and Pharmacokinetics of plasma. Started Nov 2022; status: completed.
02
Drugs
NVP-1805
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT05354713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05354713.